Loading clinical trials...
Loading clinical trials...
A Phase Ib, Open-Label, Multicohort Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Patients With Triple-Negative Breast Cancer
Conditions
Interventions
Tiragolumab
Atezolizumab
+9 more
Locations
24
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Univ of Chicago
Chicago, Illinois, United States
Levine Cancer Institute
Charlotte, North Carolina, United States
Magee-Woman's Hospital
Pittsburgh, Pennsylvania, United States
Tennessee Onc., PLLC - SCRI
Nashville, Tennessee, United States
Mater Hospital; Cancer Services
South Brisbane, Queensland, Australia
Start Date
September 28, 2020
Primary Completion Date
March 8, 2023
Completion Date
March 8, 2023
Last Updated
March 15, 2023
NCT06393374
NCT06257264
NCT05491226
NCT07525869
NCT05660083
NCT05768932
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions